2025 is anticipated to be the year with the highest number of phase 3 ADC trials read outs in breast oncology, with impact for all breast cancer subtypes.

Here’s 8 ADC breast cancer trials expected to reshape practice in 2025:

‼️When you thought you had the #SABCS24 program figured out, here’s the PRACTICE-CHANGING #PATINA trial being added!

For the impatient ones, press release here: www.businesswire.com/news/home/20...

If you’re in San Anyonio, though, make sure to attend the data presentation today by Otto Metzger!

#SABCS24 day 1 kicks off with an interesting @FDAOncology special session on drug approval. First talk tackles the approval of adjuvant ribociclib per NATALEE. Two post-marketing commitments: to provide efficacy in a broader diverse population, and to provide updates on OS. #bcsm

Small preview from Wednesday’s #SABCS24 session on the future of ADCs

Question: what do all these ongoing phase 3 ADC trials have in common?

🗓️ Dec 11, 3.30 pm, Hemisfair Ballroom 1-2

The @dfcibreastonc.bsky.social team is on its way— see you all soon in San Antonio! #SABCS24

Make sure to follow @dfcibreastonc.bsky.social for updates on the latest research efforts by DFCI BOC and for periodic research digest with recent news in breast oncology! @stolaney1.bsky.social

Impressive report in @NEJM. In a cohort of pregnant women with unusual clinical cfDNA-sequencing results, 52/107 were found to have an incidental cancer via whole-body MRI, with a sensitivity of 98.0% and specificity of 88.5%. Physical exam & labs were of limited use. www.nejm.org/doi/full/10....

10 days to #SABCS24. Excited to present at the conference the results of 4 studies, made possible by collaborations with brilliant Dana-Farber colleagues and with multiple external partners (RevealGenomics, Yale, Novartis). Come meet me at the posters on December 11th and 12th!

Is carbo needed for the neoadjuvant treatment of HER2+ BC? The #HELEN006 ph 3 trial randomized pts to TCHPx6 vs nabTHPx6. nabTHP had significantly higher pCR rate vs TCHP (66% vs 57%), with less toxicities. CompassHER-pCR trial ongoing to validate THP (x4) www.sciencedirect.com/science/arti...

The results of SONIA are out on @Nature. 1L use of palbo did not improve PFS over 2L use, but led to more AEs & costs. An evolving treatment landscape challenges its interpretation— yet it shows that sequencing trials are possible. Congrats to the authors! www.nature.com/articles/s41...

OS results of KN-522 out in @NEJM. Terrific news: adding pembro to neoadjuvant chemo for TNBC saves lives (5% 5-year Δ). Bad news: we’re stuck with giving 5 drugs to all patients with stage II-III TNBC, with permanent toxicity for many. Biomarkers, please! t.co/8S9YWOP1lr

The biparatopic anti-HER2 mAb zanidatamab is now approved for treating HER2+ biliary tract cancer. Zanidatamab simultaneously binds to the trastuzumab- and pertuzumab binding domain of HER2. Phase 3 trial ongoing in pretreated HER2+ MBC, led by Sara Tolaney. www.fda.gov/drugs/resour...

Only 3 weeks to #SABCS24, a meeting that promises to significantly impact the way we treat breast cancer. It will feature phase 3 data with novel SERDs, novel ADCs, immunotherapy, ctDNA monitoring, important biomarker analyses & so much more. Here’s my top 10 abstracts list— see you in San Antonio!